– Niels Bohr Institute - University of Copenhagen

Restricted mobility of specific functional groups reduces anti-cancer drug activity in healthy cells

Research output: Contribution to journalJournal article

Standard

Restricted mobility of specific functional groups reduces anti-cancer drug activity in healthy cells. / Longo Martins, Murillo; Ignazzi, Rosanna; Eckert, Juergen; Watts, Benjamin; Kaneno, Ramon; Zambuzzi, Willian F; Daemen, Luke; Saeki, Margarida J; Bordallo, Heloisa N.

In: Scientific Reports, Vol. 6, 22478, 2016.

Research output: Contribution to journalJournal article

Harvard

Longo Martins, M, Ignazzi, R, Eckert, J, Watts, B, Kaneno, R, Zambuzzi, WF, Daemen, L, Saeki, MJ & Bordallo, HN 2016, 'Restricted mobility of specific functional groups reduces anti-cancer drug activity in healthy cells' Scientific Reports, vol 6, 22478. DOI: 10.1038/srep22478

APA

Longo Martins, M., Ignazzi, R., Eckert, J., Watts, B., Kaneno, R., Zambuzzi, W. F., ... Bordallo, H. N. (2016). Restricted mobility of specific functional groups reduces anti-cancer drug activity in healthy cells. Scientific Reports, 6, [22478]. DOI: 10.1038/srep22478

Vancouver

Longo Martins M, Ignazzi R, Eckert J, Watts B, Kaneno R, Zambuzzi WF et al. Restricted mobility of specific functional groups reduces anti-cancer drug activity in healthy cells. Scientific Reports. 2016;6. 22478. Available from, DOI: 10.1038/srep22478

Author

Longo Martins, Murillo ; Ignazzi, Rosanna ; Eckert, Juergen ; Watts, Benjamin ; Kaneno, Ramon ; Zambuzzi, Willian F ; Daemen, Luke ; Saeki, Margarida J ; Bordallo, Heloisa N. / Restricted mobility of specific functional groups reduces anti-cancer drug activity in healthy cells. In: Scientific Reports. 2016 ; Vol. 6.

Bibtex

@article{7b00bc654442401ea1d426525672ca08,
title = "Restricted mobility of specific functional groups reduces anti-cancer drug activity in healthy cells",
abstract = "The most common cancer treatments currently available are radio- and chemo-therapy. These therapies have, however, drawbacks, such as, the reduction in quality of life and the low efficiency of radiotherapy in cases of multiple metastases. To lessen these effects, we have encapsulated an anti-cancer drug into a biocompatible matrix. In-vitro assays indicate that this bio-nanocomposite is able to interact and cause morphological changes in cancer cells. Meanwhile, no alterations were observed in monocytes and fibroblasts, indicating that this system might carry the drug in living organisms with reduced clearance rate and toxicity. X-rays and neutrons were used to investigate the carrier structure, as well as to assess the drug mobility within the bio-nanocomposite. From these unique data we show that partial mobility restriction of active groups of the drug molecule suggests why this carrier design is potentially safer to healthy cells.",
author = "{Longo Martins}, Murillo and Rosanna Ignazzi and Juergen Eckert and Benjamin Watts and Ramon Kaneno and Zambuzzi, {Willian F} and Luke Daemen and Saeki, {Margarida J} and Bordallo, {Heloisa N}",
year = "2016",
doi = "10.1038/srep22478",
language = "English",
volume = "6",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

RIS

TY - JOUR

T1 - Restricted mobility of specific functional groups reduces anti-cancer drug activity in healthy cells

AU - Longo Martins,Murillo

AU - Ignazzi,Rosanna

AU - Eckert,Juergen

AU - Watts,Benjamin

AU - Kaneno,Ramon

AU - Zambuzzi,Willian F

AU - Daemen,Luke

AU - Saeki,Margarida J

AU - Bordallo,Heloisa N

PY - 2016

Y1 - 2016

N2 - The most common cancer treatments currently available are radio- and chemo-therapy. These therapies have, however, drawbacks, such as, the reduction in quality of life and the low efficiency of radiotherapy in cases of multiple metastases. To lessen these effects, we have encapsulated an anti-cancer drug into a biocompatible matrix. In-vitro assays indicate that this bio-nanocomposite is able to interact and cause morphological changes in cancer cells. Meanwhile, no alterations were observed in monocytes and fibroblasts, indicating that this system might carry the drug in living organisms with reduced clearance rate and toxicity. X-rays and neutrons were used to investigate the carrier structure, as well as to assess the drug mobility within the bio-nanocomposite. From these unique data we show that partial mobility restriction of active groups of the drug molecule suggests why this carrier design is potentially safer to healthy cells.

AB - The most common cancer treatments currently available are radio- and chemo-therapy. These therapies have, however, drawbacks, such as, the reduction in quality of life and the low efficiency of radiotherapy in cases of multiple metastases. To lessen these effects, we have encapsulated an anti-cancer drug into a biocompatible matrix. In-vitro assays indicate that this bio-nanocomposite is able to interact and cause morphological changes in cancer cells. Meanwhile, no alterations were observed in monocytes and fibroblasts, indicating that this system might carry the drug in living organisms with reduced clearance rate and toxicity. X-rays and neutrons were used to investigate the carrier structure, as well as to assess the drug mobility within the bio-nanocomposite. From these unique data we show that partial mobility restriction of active groups of the drug molecule suggests why this carrier design is potentially safer to healthy cells.

U2 - 10.1038/srep22478

DO - 10.1038/srep22478

M3 - Journal article

VL - 6

JO - Scientific Reports

T2 - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 22478

ER -

ID: 160795942